Lonza Group (LONN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
43rd Annual J.P. Morgan Healthcare Conference 2025 summary
10 Jan, 2026Key strategic vision and initiatives
Introduced a unified vision to become a pure-play CDMO, leveraging the Lonza Engine and aiming for industry leadership through cutting-edge science, technology, and lean manufacturing.
CEO outlined a multi-step plan: establish unified vision and culture, assemble the Lonza Engine, and tune operations via focus, reshaping, elevating execution, and expansion.
Shift to a simplified operating model with three integrated business platforms, removing a management layer for faster decisions, to be implemented in Q2 2024/2025.
Decision to exit the Capsules and Health Ingredients (CHI) business to focus on core CDMO activities, with timing based on maximizing value and limited synergies.
The Lonza Engine comprises team strength, scientific ecosystem, customer partnerships, execution excellence, and scalable investment capabilities.
Market outlook and growth plans
CDMO/biopharma market expected to grow 8-10% annually, with Lonza targeting low-teens organic growth, 2-3% ahead of the market.
Growth driven by organic expansion and selective M&A, focusing on high-growth modalities like cell and gene therapy, ADCs, and biologics.
CapEx to remain mid- to high-teens % of sales, supporting infrastructure, capacity, and new technologies.
2025 outlook: CDMO sales growth approaching 20% (including CHF 500m from Vacaville acquisition), Core EBITDA margin nearing 30%.
Strategic priorities include expanding in capacity-constrained markets, diversifying advanced synthesis, and extending specialized modalities.
Execution, integration, and risk management
22 global growth projects underway, including integration of the Vacaville site, with a focus on on-time and on-budget delivery.
CapEx program for Vacaville (CHF 500m) to enhance flexibility and add technologies over 3-4 years, with careful planning to avoid operational disruption.
Ongoing focus on harmonizing systems, leveraging plug-and-play integration, and maintaining a strong global footprint, especially in Western markets.
Management confident in supply-demand balance, seeing more demand than supply in key modalities, reducing risk of overcapacity.
Emphasis on disciplined investments, operational excellence, and leveraging the Lonza Engine for sustained value creation.
Latest events from Lonza Group
- CHF 2.3bn CHI divestment finalizes pure-play CDMO focus, unlocking CHF 1.7bn+ for growth.LONN
Investor update (Q&A)9 Mar 2026 - Divestment of CHI for CHF 2.3B, CHF 1.7B upfront, finalizes pure-play CDMO shift and funds growth.LONN
Investor update6 Mar 2026 - Unified strategy targets CDMO growth, 30% margins, and CHI divestment, with strong 2025 outlook.LONN
Investor Update3 Feb 2026 - Sales up 21.7% to CHF 6.5B, margin 31.6%, 2026 growth guided at 11%-12%, dividend up 25%.LONN
H2 20253 Feb 2026 - Solid H1 2024 results with robust CDMO growth, margin resilience, and confirmed outlook.LONN
H1 20243 Feb 2026 - Unified strategy, U.S. expansion, and operational overhaul drive strong CDMO growth in 2025.LONN
44th Annual J.P. Morgan Healthcare Conference26 Jan 2026 - 2024 outlook confirmed with strong CDMO growth, major projects, and Capsules recovery in 2025.LONN
Q3 2024 TU18 Jan 2026 - CDMO growth, US expansion, and CHI exit drive 2025 margin and sales gains.LONN
H2 20249 Jan 2026 - Q1 2025 strength and confirmed outlook drive robust growth and margin momentum.LONN
Q1 2025 TU17 Nov 2025